MBCProject_4989_T2_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.580
- INTERFERON_ALPHA_RESPONSE+0.550
- E2F_TARGETS+0.540
- ALLOGRAFT_REJECTION+0.450
- INFLAMMATORY_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.410
- MTORC1_SIGNALING+0.400
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V2+0.370
Top 10 suppressed
- NOTCH_SIGNALING-0.340
- ADIPOGENESIS-0.310
- UV_RESPONSE_DN-0.300
- HEME_METABOLISM-0.290
- BILE_ACID_METABOLISM-0.240
- PEROXISOME-0.150
- TGF_BETA_SIGNALING-0.150
- MYOGENESIS-0.130
- FATTY_ACID_METABOLISM-0.120
- PROTEIN_SECRETION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20080189.TNBC | — | E | 0.847 |
| 2 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.843 |
| 3 | BS_996ZS2A4 | ATRT | — | 0.838 |
| 4 | R261 | — | — | 0.838 |
| 5 | MNG921 | — | — | 0.836 |
| 6 | MNG742 | — | — | 0.836 |
| 7 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.835 |
| 8 | TCGA-37-3792-01A-01R-0980-07 | — | cohortA1 | 0.834 |
| 9 | TCGA-K4-A4AC-01A-21R-A26T-07 | — | — | 0.818 |
| 10 | TCGA-XF-A8HE-01A-11R-A36F-07 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |